Want to see NVCR full AI Analyst Report?
NVCR Stock Chart & Stats
$12.83
-$0.69(-2.38%)
At close: 4:00 PM EST
$12.83
-$0.69(-2.38%)
Day’s Range― - ―
52-Week Range$9.82 - $18.92
Previous CloseN/A
Volume205.01K
Average Volume (3M)1.60M
Market Cap
$1.84B
Enterprise Value$1.04K
Total Cash (Recent Filing)$441.80M
Total Debt (Recent Filing)$234.94M
Price to Earnings (P/E)―
Beta1.29
Next Earnings
Jul 23, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.53
Shares Outstanding115,820,940
10 Day Avg. Volume1,419,216
30 Day Avg. Volume1,596,424
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)4.23
Price to Sales (P/S)2.20
P/FCF Ratio-19.05
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$24.17Price Target Upside88.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.59
Revenue Forecast (FY)$708.03M
Bulls Say, Bears Say
Bulls Say
Gross Margin StrengthSustained high gross margins (~75%–78%) reflect favorable consumable economics and supplier cost improvements. Durable margin leverage from recurring consumable sales supports long‑term profitability potential as active patient volumes scale, helping absorb fixed R&D and commercialization costs.
Recurring Patient Base GrowthActive patient growth underpins a recurring revenue model tied to ongoing device use and consumable replacement. A steadily expanding installed base increases revenue predictability, creates upsell and retention opportunities, and enhances operating leverage as unit economics improve with scale across markets.
Regulatory / Indication ExpansionCE Mark for pancreatic cancer materially expands addressable market into a high‑unmet oncology segment. Regulatory approval and imminent German rollout enable durable new revenue streams, stronger clinical credibility, and a foundation for multi‑market commercialization in a therapy area with limited alternatives.
Bears Say
Negative Cash GenerationTrailing‑twelve‑month negative operating and free cash flow indicate ongoing cash burn despite margin strength. Continued reliance on external financing or drawdown of liquidity risks capital constraints over time and can pressure strategic investments or force dilution if losses persist.
Clinical Trial Setback (TRIDENT)A Phase 3 miss for earlier TTFields initiation limits evidence for a broader label expansion in glioblastoma. That constrains long‑term adoption scenarios tied to earlier‑stage use, may slow anticipated incremental market opportunities, and forces reassessment of trial strategy and commercial expectations.
Reimbursement Timing UncertaintyProlonged payer decision timelines create a durable barrier to realizing revenue from newly approved indications. Even with regulatory clearance, multi‑year reimbursement delays can restrict patient access, depress near‑term uptake, and lengthen the payback period on launch investments.
NovoCure News
NVCR FAQ
What was NovoCure Ltd.’s price range in the past 12 months?
NovoCure Ltd. lowest stock price was $9.82 and its highest was $18.92 in the past 12 months.
What is NovoCure Ltd.’s market cap?
NovoCure Ltd.’s market cap is $1.84B.
When is NovoCure Ltd.’s upcoming earnings report date?
NovoCure Ltd.’s upcoming earnings report date is Jul 23, 2026 which is in 3 days.
How were NovoCure Ltd.’s earnings last quarter?
NovoCure Ltd. released its earnings results on Apr 30, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.512 by -$0.108.
Is NovoCure Ltd. overvalued?
According to Wall Street analysts NovoCure Ltd.’s price is currently Undervalued.
Does NovoCure Ltd. pay dividends?
NovoCure Ltd. does not currently pay dividends.
What is NovoCure Ltd.’s EPS estimate?
NovoCure Ltd.’s EPS estimate is -0.33.
How many shares outstanding does NovoCure Ltd. have?
NovoCure Ltd. has 115,820,940 shares outstanding.
What happened to NovoCure Ltd.’s price movement after its last earnings report?
NovoCure Ltd. reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.512. Following the earnings report the stock price went up 27.494%.
Which hedge fund is a major shareholder of NovoCure Ltd.?
Currently, no hedge funds are holding shares in NVCR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NovoCure Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$24.17 (88.36% Upside)
$24.17 (88.36% Upside)
Blogger Sentiment
Bullish
NVCR Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 38.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 3.8%
Last 30 Days ▲ 2.9%
Last 30 Days ▲ 2.9%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.78%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.91%
Trailing 12-Months
Company Description
NovoCure Ltd.
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.
NVCR Net revenue Breakdown
68.67% U.S.
11.82% Germany
8.74% Japan
6.22% Other EMEA
4.56% Greater China
NVCR Stock 12 Month Forecast
Average Price Target
$24.17
▲(88.36% Upside)
Technical Analysis
Ownership Overview
2.74% Insiders
22.58% Mutual Funds
0.16% Other Institutional Investors
57.86% Public Companies and
Individual Investors